Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell

• Published in: BMC biotechnology Vol. 24; no. 1; p. 1
• Main Authors: Taheri, Fatemeh Hajari, Hassani, Mahmoud, Sharifzadeh, Zahra, Behdani, Mahdi, Abdoli, Shahryar, Sayadi, Mahtab, Bagherzadeh, Kowsar, Arashkia, Arash, Abolhassani, Mohsen
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 04.01.2024; BioMed Central; BMC
• Subjects: Antibodies; Antigens; Cancer; Cancer immunotherapy; Care and treatment; CD25 antigen; CD28 antigen; CD69 antigen; Cells; Chimeric antigen receptor (CAR); Chimeric antigen receptors; Complications and side effects; Cytokines; Cytolytic activity; Cytotoxicity; domain; Health aspects; Hinge; IgG1 CH2-CH3; Immunoglobulin G; Immunotherapy; interleukin-2; Intracellular; Intracellular signalling; Ligands; Lymphocytes; Lymphocytes T; Nanobodies; neoplasms; Patient outcomes; secretion; Solid tumors; Spacer domain; T cells; T-lymphocytes; Tumor necrosis factor; Vascular endothelial growth factor; vascular endothelial growth factor receptor-2; VEGFR2; γ-Interferon; Iran; VEGFR2; Chimeric antigen receptor (CAR); Spacer domain; Hinge; IgG1 CH2-CH3

The chimeric antigen receptor-expressing T (CAR-T) cells for cancer immunotherapy have obtained considerable clinical importance. CAR T cells need an optimized intracellular signaling domain to get appropriately activated and also for the proper antigen recognition, the length and composition of the...